Advances in Therapy最新文献

{"title":"Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review","authors":"Piotr Wiland, Charlotte Both, Norman B. Gaylis, Russell D. Cohen, Jonas Halfvarson, Lena Lemke, Oliver von Richter, Andrew Blauvelt","doi":"10.1007/s12325-025-03181-z","DOIUrl":"10.1007/s12325-025-03181-z","url":null,"abstract":"","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2970 - 2971"},"PeriodicalIF":3.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03181-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LDL-C Reduction with Evolocumab Among Patients with ASCVD in China: Real-World Evidence from Tianjin Metropolitan Area","authors":"Liming Zhao,&nbsp;Jiamei Liu,&nbsp;Yin Liu,&nbsp;Zhenna Huang,&nbsp;Xuxiao Ye,&nbsp;Jeff L. Lange,&nbsp;Nafeesa Dhalwani,&nbsp;Fan Yang,&nbsp;Zizhao Zhang,&nbsp;Kangyin Chen,&nbsp;Hao Zhang,&nbsp;Jifang Zhou","doi":"10.1007/s12325-025-03199-3","DOIUrl":"10.1007/s12325-025-03199-3","url":null,"abstract":"<div><h3>Introduction</h3><p>Clinical trials have shown that adding evolocumab to statin therapy reduces low-density lipoprotein cholesterol (LDL-C) levels by approximately 60%. Given differences in patient characteristics and standards of care between trial and real-world settings, we conducted a cohort study to evaluate the LDL-C reduction achieved with evolocumab in clinical practice of China.</p><h3>Methods</h3><p>The data source was the Tianjin Regional Healthcare Database (TRHD), which includes linked electronic health records (EHR) of public hospitals serving over 15 million residents in the Tianjin metropolitan area. The study cohort included adult patients with atherosclerotic cardiovascular disease (ASCVD) who added evolocumab to their statin therapy between 2019 and 2023. Key inclusion criteria were use of the same statin intensity before and after evolocumab initiation and available LDL-C values at baseline (within 90 days before initiation) and follow-up (15–90 days after initiation). Descriptive statistics were used to analyze LDL-C change between baseline and follow-up. To provide the context for evolocumab use and for study method assessment, we included another cohort of patients with stable statin intensity (unchanged for at least 180 days)—a cohort with minimal clinical expectation of further LDL-C change over time.</p><h3>Results</h3><p>At baseline, the median (interquartile range [IQR]) LDL-C level was 3.44 (2.73–4.15) mmol/L in the evolocumab cohort (<i>n</i> = 395) and 2.20 (1.72–2.92) mmol/L in the stable statin cohort (<i>n</i> = 4160). At follow-up, the mean (95% confidence interval [CI]) percentage reduction in LDL-C levels was 63.0% (60.5–65.5%) in the evolocumab cohort and 2.5% (0.3–4.7%) in the stable statin cohort.</p><h3>Conclusions</h3><p>LDL-C reductions in patients who added evolocumab to statin therapy in real-world clinical practice in China align with reductions observed in clinical trials.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2874 - 2887"},"PeriodicalIF":3.4,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison","authors":"Marcin Dzienis,&nbsp;Ali Mojebi,&nbsp;Sam Keeping,&nbsp;Christopher M. Black,&nbsp;Hilde Giezek,&nbsp;Niroshini Naicker,&nbsp;Chiara Vanetta,&nbsp;Julie E. Park,&nbsp;Keith Chan,&nbsp;Sanjay Merchant,&nbsp;Dandan Zheng","doi":"10.1007/s12325-025-03144-4","DOIUrl":"10.1007/s12325-025-03144-4","url":null,"abstract":"<div><h3>Introduction</h3><p>Based on the results of KEYNOTE-048 (NCT02358031), first-line standard-of-care treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) includes pembrolizumab alone or with platinum and fluorouracil (5-FU). Results from the single-arm KEYNOTE-B10 (NCT04489888) showed promising antitumor activity and a manageable safety profile offering an alternative pembrolizumab and chemotherapy regimen (KN-B10), with paclitaxel replacing 5-FU. With KEYNOTE-B10 being a non-comparative trial, this study aims to estimate the comparative efficacy of KN-B10 versus alternative first-line systemic treatments for R/M HNSCC via an indirect treatment comparison analysis.</p><h3>Methods</h3><p>A systematic literature review (October 2023) identified six connected randomized controlled trials with similar eligibility criteria to KEYNOTE-B10. Interventions included cetuximab + platinum + 5-FU (EXTREME), cetuximab + cisplatin + docetaxel (TPEx), pembrolizumab + platinum + 5-FU (KN-048), platinum + 5-FU, cisplatin + paclitaxel, cisplatin, 5-FU, and methotrexate. To connect KEYNOTE-B10 to the network, individual patient-level data were weighted to match the population characteristics of the most similar trial in the network (KEYNOTE-048). The comparative efficacy of KN-B10 versus other interventions was estimated via fixed-effect Bayesian network meta-analyses. Due to violations of the proportional-hazards assumption, fractional polynomials were used to model overall survival (OS) and progression-free survival (PFS).</p><h3>Results</h3><p>For objective response, KN-B10 was comparable to EXTREME and TPEx and more efficacious than all other identified treatments (range of odds ratios [ORs]: 1.69–11.75), including KN-048 (OR: 1.69; 95% credible interval: 1.01–2.81). For OS and PFS, KN-B10 was comparable to EXTREME (with improvements in OS after month 12), TPEx, and KN-048. KN-B10 improved OS versus platinum + 5-FU (range of time-varying hazard ratios: 0.60–0.18; months 9–60), cisplatin + paclitaxel (0.53–0.24; 9–36), cisplatin (0.59–0.32; 6–24), 5-FU (0.58–0.20; 6–36), and methotrexate (0.61–0.07; 6–60). KN-B10 improved PFS versus platinum + 5-FU (0.60–0.31; 3–36).</p><h3>Conclusion</h3><p>The improved or comparable efficacy of KN-B10 versus alternative first-line interventions in terms of relevant clinical outcomes, as shown in this study, supports its recommendations for the treatment of R/M HNSCC.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2690 - 2707"},"PeriodicalIF":3.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone Deficiency","authors":"Andrew R. Hoffman,&nbsp;Subhara Raveendran,&nbsp;Janna Manjelievskaia,&nbsp;Allison S. Komirenko,&nbsp;Isabelle Winer,&nbsp;Jennifer Cheng,&nbsp;Machaon Bonafede,&nbsp;Jessamine P. Winer-Jones,&nbsp;Paul Miner,&nbsp;Alden R. Smith","doi":"10.1007/s12325-025-03188-6","DOIUrl":"10.1007/s12325-025-03188-6","url":null,"abstract":"<div><h3>Introduction</h3><p>Adult growth hormone deficiency (GHD) is an endocrine disorder associated with increased morbidity and poor quality of life. The purpose of this study was to describe the clinical characteristics, treatment patterns, and prevalence of individuals at risk for adult GHD and individuals with confirmed adult GHD in the United States (US).</p><h3>Methods</h3><p>Using Veradigm Network electronic health records linked to claims, this study identified adults with a high likelihood of adult GHD based on having ≥ 1 of the following between January 1, 2017 and December 31, 2021: diagnosis of hypopituitarism or ≥ 1 related condition, such as Cushing disease, ≥ 3 pituitary hormone deficiencies other than GHD, ≥ 3 pituitary hormone treatments other than growth hormone (GH), or ≥ 1 prescription for GH. Index date was the earliest qualifying event. Individuals were stratified by GH level on or before index date: confirmed adult GHD (&lt; 3 ng/mL), at risk for adult GHD (no test result), ruled-out (≥ 3 ng/mL).</p><h3>Results</h3><p>US prevalence of adult GHD was estimated to be between 0.2 (confirmed) and 37.0 (confirmed + at-risk) per 100,000. Among 268 individuals with confirmed adult GHD and 54,310 at risk for adult GHD, mean age was 50 years old, and a majority were female. GH treatment was initiated in 9.7% of confirmed individuals and 3.1% of those at risk for adult GHD. Among confirmed and at-risk individuals, prevalence of endocrine-related conditions was higher in treated individuals, whereas prevalence of several metabolic and cardiovascular comorbidities was higher in those untreated. Only 32.2% of individuals who initiated treatment during the follow-up period were persistent until the end of follow-up.</p><h3>Conclusions</h3><p>Our findings report US prevalence of adult GHD and suggest that adult GHD is commonly underdiagnosed in the US. Factors contributing to low rates of adult GHD diagnosis and treatment warrant further research.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2853 - 2873"},"PeriodicalIF":3.4,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03188-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma","authors":"Reynold A. Panettieri Jr.,&nbsp;Monica Kraft,&nbsp;Mario Castro,&nbsp;Magdalena Bober,&nbsp;Andrew W. Lindsley,&nbsp;Max Shelkrot,&nbsp;Christopher S. Ambrose","doi":"10.1007/s12325-025-03184-w","DOIUrl":"10.1007/s12325-025-03184-w","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with moderate or severe, uncontrolled asthma are often prescribed biologic therapies to improve disease control and reduce asthma exacerbations. The efficacy of different biologics in reducing asthma exacerbations associated with hospitalization or an emergency department (ED) visit has varied across randomized controlled trials (RCTs). This study summarizes published US Food and Drug Administration-approved biologic efficacy data for exacerbations that required hospitalization or an ED visit in patients with moderate or severe, uncontrolled asthma.</p><h3>Methods</h3><p>A PubMed literature search (24 May 2024) identified phase 2b/3 RCTs of omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, or tezepelumab. Annualized asthma exacerbation rate (AAER) ratios for exacerbations that required hospitalization or an ED visit, or hospitalization regardless of an ED visit, were extracted. A pooled efficacy estimate of the AAER ratio for exacerbations that required hospitalization or an ED visit across the RCTs was assessed using a meta-analysis based on a random effects model. The percentage of total variation across all included RCTs that was due to heterogeneity was calculated (<i>I</i>²).</p><h3>Results</h3><p>Among 308 articles identified, nine publications describing 10 RCTs reported relevant AAER ratio data. No suitable omalizumab data were identified. In all trials, biologic treatment showed a reduction versus placebo in the AAER for exacerbations that required hospitalization or an ED visit, except in one of two benralizumab studies and both reslizumab studies. The pooled efficacy estimate showed a 56% reduction (95% CI 37–69) in the AAER for exacerbations requiring hospitalization or an ED visit (<i>I</i>², 59.93%; <i>p</i> = 0.0075). One of three mepolizumab trials and both tezepelumab trials showed a reduction versus placebo in the AAER for exacerbations that required hospitalization regardless of an ED visit.</p><h3>Conclusion</h3><p>These findings suggest that there may be differential effects of biologics in reducing exacerbations that require hospitalization or an ED visit in patients with moderate or severe, uncontrolled asthma.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2679 - 2689"},"PeriodicalIF":3.4,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03184-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Care for People with Chronic Respiratory Diseases: Taking a Policy Lens","authors":"Aislinn Santoni,&nbsp;Suzanne Wait,&nbsp;Job F. M. van Boven,&nbsp;Zachary Desson,&nbsp;Christine Jenkins,&nbsp;Ee Ming Khoo,&nbsp;Tonya Winders,&nbsp;Dawei Yang,&nbsp;Arzu Yorgancioglu","doi":"10.1007/s12325-025-03191-x","DOIUrl":"10.1007/s12325-025-03191-x","url":null,"abstract":"<div><p>Chronic respiratory diseases (CRDs) affect almost 470 million people worldwide, and this number is growing. CRDs take a significant toll on the capacity of health systems and economies, and their effect on people’s lives can be devastating. Despite high rates of prevalence and mortality, CRDs are underprioritised by policymakers and governments. Tackling these conditions will require a holistic, multisectoral approach, including government-led strategies for prevention, diagnosis, management and investment in research. In this article, we provide a clear rationale for prioritising CRDs to advance population health. Proactive steps in countries of all income levels must be taken promptly to limit the growing prevalence and impact of CRDs both now and in the future.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2569 - 2586"},"PeriodicalIF":3.4,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03191-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments","authors":"Kazi Islam,&nbsp;Rahib Islam,&nbsp;Ivan Nguyen,&nbsp;Hassan Malik,&nbsp;Humza Pirzadah,&nbsp;Barsha Shrestha,&nbsp;Isabella B. Lentz,&nbsp;Sahar Shekoohi,&nbsp;Alan D. Kaye","doi":"10.1007/s12325-025-03185-9","DOIUrl":"10.1007/s12325-025-03185-9","url":null,"abstract":"<div><p>Diabetes mellitus is a metabolic disorder, characterized by elevated blood sugar levels (hyperglycemia) and insulin dysregulation. This disease is associated with morbidity and mortality, including significant potential vascular complications. High levels of hyperglycemia lead to not only elevated levels of reactive oxygen species but also advanced glycation end products, which are detrimental to the vascular endothelium and reduce protective compounds such as nitric oxide and prostacyclin. This damage contributes to the development of both macrovascular and microvascular complications. The present investigation explores the pathophysiological mechanisms of diabetic vascular complications and evaluates current management strategies, including lifestyle modifications, pharmacological treatments, and emerging therapies. The review underscores the importance of ongoing progress in diabetes management and patient education to lead to optimal patient-health outcomes and quality of life for individuals with diabetes mellitus.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2659 - 2678"},"PeriodicalIF":3.4,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03185-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-treatment with Gabapentinoid and Japanese Herbal Medicine Goshajinkigan for CIPN is Associated with Longer Duration and Higher Dose of Chemotherapy","authors":"Kanako Miyano,&nbsp;Yasuhito Uezono,&nbsp;Takuhiro Yamaguchi,&nbsp;Wataru Hashimoto,&nbsp;Satoshi Komoriya","doi":"10.1007/s12325-025-03173-z","DOIUrl":"10.1007/s12325-025-03173-z","url":null,"abstract":"<div><h3>Introduction</h3><p>In Japan, both gabapentinoids and the Japanese traditional herbal medicine goshajinkigan (GJG) are used to manage chemotherapy-induced peripheral neuropathy (CIPN); however, evidence for their effectiveness is inconclusive. Patients with CIPN experience reduced quality of life and often undergo reductions in dose or discontinuation of chemotherapy. Therefore, this retrospective cohort study used a real-world database to examine the efficacy of gabapentinoids and GJG therapy for patients with CIPN by evaluating chemotherapy duration and dose.</p><h3>Methods</h3><p>Data from 145,384 patients diagnosed with CIPN while receiving platinum- or taxane-based chemotherapy between April 1, 2008 and March 31, 2022 were stratified by CIPN treatment: simultaneous gabapentinoid (mirogabalin or pregabalin) plus GJG (prescription dates overlap); non-simultaneous gabapentinoid plus GJG (prescription dates do not overlap); gabapentinoid alone; GJG alone; and neither gabapentinoids nor GJG. Duration and dose of chemotherapy were the primary outcomes.</p><h3>Results</h3><p>Treatment with either a gabapentinoid or GJG alone was associated with longer duration and higher doses of chemotherapy versus neither gabapentinoids nor GJG in patients treated with carboplatin, cisplatin, or paclitaxel. Combined gabapentinoid plus GJG treatment elicited further longer duration and higher doses of chemotherapy versus gabapentinoid alone or GJG alone in patients treated with carboplatin, oxaliplatin, cisplatin, paclitaxel, or docetaxel. When stratified by cancer type, similar trends were observed regarding combination gabapentinoid plus GJG treatment among patients with colorectal cancer treated with oxaliplatin and patients with gastric, lung, or breast cancer treated with paclitaxel.</p><h3>Conclusion</h3><p>Combination treatment with gabapentinoid plus GJG might prevent reductions in dose or discontinuation of chemotherapy, and might be effective for the treatment of CIPN.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2833 - 2852"},"PeriodicalIF":3.4,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03173-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Situation and Prospects of Digital Therapeutics in the Field of Liver Diseases in China","authors":"Junfeng Chen,&nbsp;Shaoquan Zhang,&nbsp;Xian Cao,&nbsp;Dili Daer,&nbsp;Bingliang Lin","doi":"10.1007/s12325-024-03086-3","DOIUrl":"10.1007/s12325-024-03086-3","url":null,"abstract":"<div><p>Digital therapeutics have developed rapidly in recent years, providing a new method for disease management. The burden of liver diseases in China is heavy, and there are obvious problems in disease management. This paper expounds on the definition and classification of digital therapeutics, introduces their application in liver disease treatment and management in detail, and analyzes their development prospects in the field of liver diseases and future challenges.</p><p>Graphical abstract available for this article.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2639 - 2658"},"PeriodicalIF":3.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-024-03086-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study","authors":"Marc Evans,&nbsp;William Evans,&nbsp;Fiona Godbeer,&nbsp;Laurienne Edgar,&nbsp;Erik Spaepen,&nbsp;Alun Lloyd Davies","doi":"10.1007/s12325-025-03194-8","DOIUrl":"10.1007/s12325-025-03194-8","url":null,"abstract":"<div><h3>Introduction</h3><p>Tirzepatide, an anti-obesity medication, demonstrated significant weight loss efficacy in the SURMOUNT-1 randomized controlled trial. This analysis evaluates the cost-efficiency of tirzepatide in the UK by linking clinical outcomes to drug acquisition costs.</p><h3>Methods</h3><p>Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide’s (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome. Cost needed to treat and cost-to-target analyses were performed to determine the economic value of achieving specific weight loss goals and improvements in body mass index (BMI).</p><h3>Results</h3><p>Tirzepatide demonstrated significant weight loss, with greater reductions at higher doses. Cost/kilogram of weight loss at 72W was £102.86, £85.41, and £89.24 for 5, 10, and 15 mg, respectively. Average per-patient costs at 72W for 5% weight loss were £1852, £1971, and £2186 (5, 10, and 15 mg, respectively; average 28-day costs: £102.90, £109.52, and £121.47). Average per-patient costs for 10% weight loss were £2258, £2209, and £2338 (28-day costs: £125.43, £122.69, and £129.88). The 15 mg dose was the most cost-efficient for achieving higher weight loss targets (15% and 20%).</p><h3>Conclusions</h3><p>In the SURMOUNT-1 study, tirzepatide was cost-efficient in the UK for weight management, demonstrating favourable economic outcomes relative to its efficacy in reducing body weight and improving BMI. It provided additional health benefits, including reduced risks for type 2 diabetes and cardiovascular events and improved mental health. Tirzepatide contributed to cost savings and improved efficiency within the healthcare system by decreasing the burden of obesity-related conditions, thus enhancing overall healthcare resource allocation. These findings support its inclusion in clinical practice guidelines and healthcare formularies. Further research is needed to explore real-world adherence, patient-centred outcomes, and the long-term sustainability of weight loss with tirzepatide.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2821 - 2832"},"PeriodicalIF":3.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03194-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}